MARLBOROUGH, Mass.--(BUSINESS WIRE)--Cytyc Corporation (Nasdaq: CYTC), a leading provider of surgical and diagnostic products targeting women’s health and cancer diagnostics, today announced a new multi-year agreement with Quest Diagnostics (NYSE: DGX) for the ThinPrep® Pap Test. Quest Diagnostics, the nation’s leading provider of diagnostic testing, information and services, first introduced the ThinPrep Pap Test in 1997 and has been instrumental in driving acceptance of liquid-based Pap testing among physicians nationally. The new agreement will run through the end of 2010. Additional terms and conditions were not disclosed.
